GlassScriptPhysician profile
John B Savage
NPI 1942265483
$2,441.08
in general payments reported to CMS, 2019-2025
27 companies · $559 in 2025
The $559 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $355 · 2021: $431 · 2022: $340 · 2023: $149 · 2024: $364 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $289.56 | 2019-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $234.23 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $214.33 | 2020-2024 | Rexulti |
| Abbvie INC. | $188.17 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.78 | 2021-2025 | Caplyta |
| Novo Nordisk INC | $136.70 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $130.04 | 2020-2022 | |
| Amgen INC. | $119.07 | 2019-2025 | Repatha, Otezla, Otezla |
| Lundbeck LLC | $113.68 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $108.46 | 2020-2024 | Airsupra |
| Eisai INC. | $94.56 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $91.12 | 2025 | Austedo Xr |
| Glaxosmithkline, LLC. | $79.21 | 2019-2024 | Trelegy Ellipta |
| Dexcom, INC. | $75.50 | 2022-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $64.20 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $45.44 | 2024-2025 | |
| Exact Sciences Corporation | $44.89 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $35.07 | 2020-2021 | |
| Smith+Nephew, INC. | $32.49 | 2025 | Pico |
| Adlon Therapeutics L.P. | $27.63 | 2021 | |
| Merck Sharp & Dohme LLC | $26.91 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $24.59 | 2025 | |
| Alkermes, INC. | $23.52 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.73 | 2024 | Voquezna |
| Boston Scientific Corporation | $17.81 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.51 | 2022 | |
| Pfizer INC. | $13.88 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Savage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.